share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4：持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/20 07:13
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 26,082 shares of the company's Class A Common Stock on August 15, 2024. The transaction was carried out at a price of $6.69 per share, resulting in a total value of approximately $174,488. Following the sale, Gibson directly holds 732,656 shares in the company. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 26,082 shares of the company's Class A Common Stock on August 15, 2024. The transaction was carried out at a price of $6.69 per share, resulting in a total value of approximately $174,488. Following the sale, Gibson directly holds 732,656 shares in the company. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
2024年8月15日，Recursion Pharmaceuticals的CEO Christopher Gibson以每股6.69美元的價格完成了26,082股A類普通股的銷售，總價值約爲174,488美元。銷售後，Gibson直接持有公司的732,656股股票。該銷售是通過交易代碼「F」執行，以涵蓋交付或扣留證券的行權價格或稅收負債的支付。
2024年8月15日，Recursion Pharmaceuticals的CEO Christopher Gibson以每股6.69美元的價格完成了26,082股A類普通股的銷售，總價值約爲174,488美元。銷售後，Gibson直接持有公司的732,656股股票。該銷售是通過交易代碼「F」執行，以涵蓋交付或扣留證券的行權價格或稅收負債的支付。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間